Recorded Presentation from the NCCN Pharmacy Updates: Management of Immunotherapy-Associated Oral Toxicities
Oncology pharmacists are vital members of the oncology team with specialized knowledge of anticancer therapy and can help navigate therapeutic interventions, contributing to selection, dosing, monitoring, evaluation, and education of medications to improve oral immune-related adverse event outcomes.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
NCCN 2024 Pharmacy Updates: A Webinar Series
This program will provide up-to-date knowledge and skills related to the management of cancer and highlight the importance of interprofessional care and collaboration to ensure the best possible outcomes for patients with cancer.
Category
Format
Credits
Updates to the Management of Multiple Myeloma
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. Clinicians would benefit from additional education on the available agents and understanding how to individualize treatment to improve outcomes of patients with MM.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Updates in the Management of Locally Advanced Rectal Cancer
The management of locally advanced rectal cancer is rapidly changing based on new data from several clinical trials on the topic. Some of the important updates have involved new treatment options for dMMR/MSI-H rectal cancers and selective usage of radiation or surgery, based on reassessment of response during perioperative therapy.
Category
  • Rectal Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
New Targeted Therapies for Metastatic Non-Small Cell Lung Cancer
Clinicians need to be aware of the most recent recommendations about biomarker testing and the appropriate use of new targeted therapies (including sequencing these therapies, assessing and managing side effects from these therapies), so they can select the most appropriate therapy for their patients with metastatic NSCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Management of MSI-H/dMMR Upper and Lower Gastrointestinal Cancers
Clinicians need to be informed about the importance of MSI-H/dMMR testing in patients with GI tumors and updated on the most recent clinical evidence to ensure that they select the most appropriate treatment options for their patients.
Category
  • Anal Carcinoma
  • Colorectal Cancer
  • Gastric/Esophageal Cancer
  • Rectal Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Team-Based Case Review: Colorectal Cancer
As a result of the therapeutic advances and clinical research affecting the management of patients with cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.
Category
  • Colorectal Cancer
  • Rectal Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Updates to the Management of HR-Positive, HER2-Negative Breast Cancer
The treatment landscape of HR-positive, HER2-negative breast cancer is evolving constantly in the adjuvant as well as the metastatic settings. The decision-making process of treatment selection should involve careful consideration of the available evidence and a detailed discussion of the associated benefits and risks with patients. Staying up to date with the available treatment options is important to integrate new evidence-based data into clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Management of Renal Cell Carcinoma
To offer optimal care to patients with RCC, clinicians must have a deep understanding of the key trial results and know how to best contextualize evidence to optimize considerations at key decision points along the RCC treatment continuum.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Updates in the Treatment of Metastatic Urothelial Cancer
Systemic therapy options for advanced bladder cancer continue to expand. The approvals of new therapies or combinations of therapies and emerging clinical trial data continue to impact the treatment landscape, and education on the topic would be valuable to help clinicians stay up to date with the latest research
Category
  • Bladder Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation

Pages